The market for hepatitis B drugs in China is expected to grow 135% by 2012, according to a new report from Decision Resources. From $340 million in 2007, sales of hepatitis B treatments will increase to $800 million over the five years, a CAGR of 18%. Part of the reason behind the high dollar value of drugs for this population is that the nucleoside/nucleotide analogue class of drugs often used to treat the disease must be given long term, often for the rest of a patient’s life. More details...

Stock Symbols: (NYSE: BMY) (VX: ROG) (NYSE: SGP) (NYSE: GSK)